Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways
Authors
Koulnis, MiroslavPorpiglia, Ermelinda
Porpiglia, P. Alberto
Liu, Ying
Hallstrom, Kelly N.
Hidalgo, Daniel
Socolovsky, Merav
Document Type
Journal ArticlePublication Date
2012-02-02Keywords
AnimalsApoptosis Regulatory Proteins
Cell Survival
Embryo, Mammalian
Embryonic Development
Erythroid Precursor Cells
Erythropoiesis
Liver
Male
Membrane Proteins
Mice
Mice, Inbred BALB C
Mice, Knockout
Proto-Oncogene Proteins
STAT5 Transcription Factor
Signal Transduction
Stress, Physiological
bcl-X Protein
Hematology
Oncology
Pediatrics
Metadata
Show full item recordAbstract
Survival signaling by the erythropoietin (Epo) receptor (EpoR) is essential for erythropoiesis and for its acceleration in hypoxic stress. Several apparently redundant EpoR survival pathways were identified in vitro, raising the possibility of their functional specialization in vivo. Here we used mouse models of acute and chronic stress, including a hypoxic environment and β-thalassemia, to identify two markedly different response dynamics for two erythroblast survival pathways in vivo. Induction of the antiapoptotic protein Bcl-x(L) is rapid but transient, while suppression of the proapoptotic protein Bim is slower but persistent. Similar to sensory adaptation, however, the Bcl-x(L) pathway "resets," allowing it to respond afresh to acute stress superimposed on a chronic stress stimulus. Using "knock-in" mouse models expressing mutant EpoRs, we found that adaptation in the Bcl-x(L) response occurs because of adaptation of its upstream regulator Stat5, both requiring the EpoR distal cytoplasmic domain. We conclude that survival pathways show previously unsuspected functional specialization for the acute and chronic phases of the stress response. Bcl-x(L) induction provides a "stop-gap" in acute stress, until slower but permanent pathways are activated. Furthermore, pathologic elevation of Bcl-x(L) may be the result of impaired adaptation, with implications for myeloproliferative disease mechanisms.Source
Blood. 2012 Feb 2;119(5):1228-39. Epub 2011 Nov 15. doi:10.1182/blood-2011-07-365346DOI
10.1182/blood-2011-07-365346Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43334PubMed ID
22086418Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1182/blood-2011-07-365346